Benjamin D. Singer

Partner

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

pdf

Benjamin Singer represents multinational corporations and their boards and executives in high-stakes criminal and civil investigations by the US Department of Justice, Securities and Exchange Commission, and other federal and state agencies. Ben joined O’Melveny after a decade at DOJ, where he most recently served as Chief of the Department of Justice’s Market Integrity and Major Frauds Unit. In this role, Ben was the lead prosecutor on several of the largest cross-border cases in DOJ history, including Volkswagen’s alleged evasion of US emissions standards, the foreign exchange manipulation cases, and cases alleging LIBOR manipulation. 

Ben has been recognized by Chambers USA as a leading lawyer in Washington, DC for White Collar Crime and Government Investigations. The 2021 edition of Chambers USA quotes a client who describes Ben as a “very smart, talented and tenacious lawyer” and notes that “he has handled multiple, large-scale investigations, and has done so with finesse and an attention to detail that is particularly admirable.” Ben has also been recognized by The Legal 500 US, named a Washington DC “Super Lawyer” for white collar criminal defense, and named a future leader in the investigations bar by Who’s Who Legal and Global Investigations Review

VIEW MORE

Government Experience

  • Chief, Market Integrity and Major Frauds Unit, Fraud Section, Criminal Division, U.S. Department of Justice (2014–2018)
  • Chief, Health Care Fraud Unit, Fraud Section, Criminal Division, U.S. Department of Justice (2013–2014)
  • Assistant Chief, Fraud Section, Criminal Division, U.S. Department of Justice (2011–2014)
  • Trial Attorney, Fraud Section, Criminal Division, U.S. Department of Justice (2009–2011)

Honors & Awards

  • Chambers USA, Litigation: White-Collar Crime & Government Investigations (2021)
  • Washington DC “Super Lawyers,” White Collar Criminal Defense (2020, 2021)
  • Who’s Who Legal Global Investigations Review – Future Leader, Investigations (2019, 2020, 2021)
  • The Legal 500 US Recommended Lawyer for Antitrust in Cartel, Civil Litigation/Class Actions: Defense, and Merger Control (2019)
  • Attorney General’s Award for Distinguished Service (2016)
  • Attorney General’s Award for Fraud Prevention (2012)
  • Department of Justice Director’s Award (2018)
  • Assistant Attorney General’s Award for Exceptional Service (2011, 2015)
  • Assistant Attorney General’s Award for Distinguished Service (2010, 2014)
  • Inspector General of the Department of Health and Human Services’ Integrity Award (2011)

Admissions

Bar Admissions

  • Washington, DC
  • New York

Court Admissions

  • US District Court, District of Columbia
  • US District Court, Southern and Eastern Districts of New York

Education

  • Cornell Law School, J.D., 2002
  • The College of William & Mary, B.A., 1999: with honors

Professional Activities

Publications

  • “Trends in US Criminal FCPA Enforcement – Record Numbers Being Driven by Increased Resources and Cooperation Incentives,” Financier Worldwide (Jan. 22, 2020)
  • “DOJ Eases Requirements in Corporate Enforcement Policy Update,” O’Melveny & Myers LLP Client Alert (Nov. 26, 2019)
  • “DOJ Lifts the Curtain on Evaluating Claims of ‘Inability to Pay,’” O’Melveny & Myers LLP Client Alert (Oct. 16, 2019)
  • “International Financial Fraud Enforcement Trends in a Globalized World,” The Review of Securities & Commodities Regulation (Dec. 19, 2018)
  • “Preserving Privilege in Cross-Border Internal Investigations,” Global Investigations Review (Oct. 1, 2018)
  • “Second Circuit Decision Limits FCPA Jurisdiction as to Foreign Nationals Outside the United States,” O’Melveny & Myers LLP Client Alert (Aug. 28, 2018)
  • “Federal Appeals Court Refuses to Void Criminal Service of Process on Counsel for Foreign Corporation Making Limited Appearance,” O’Melveny & Myers LLP Client Alert (Aug. 23, 2018)
  • “California Decision Distorts Bank Liability Under FIRREA,” Law360 (July 17, 2018)

Speaking Engagements

  • HCCA Compliance Institute, “Managed Care Enforcement Trends and Compliance Risks” (2020, 2021)
  • ABA National Institute on Healthcare Fraud, “Managed Care Fraud & Enforcement” (2019)
  • HCCA Compliance Institute, “Managed Care Fraud: Enforcement and Compliance” (2019)
  • University of Texas School of Law, Annual Government Enforcement Institute, Panelist, “Financial Fraud Enforcement Trends: A Conversation with the SEC and DOJ” (2018); Keynote Speaker (2017); Panelist, “Current Trends in Criminal and Civil Investigations” (2015, 2018, 2019)
  • ABA National Institute on White Collar Crime, “Securities Enforcement in 2018 and Beyond” (2018)
  • Practicing Law Institute, Swaps and Derivatives and Market Enforcement, Panelist, “Perspectives from Government Agencies” (2016, 2017)
  • SEC & DOJ Hot Topics, Panelist, “Current Developments Materially Affecting Corporations, Financial Institutions, Individuals” (2016, 2017)
  • SIFMA, Compliance & Legal Annual Seminar, Panelist, “US and Global Market Abuses: Price Manipulation and Other Issues” (2016)
  • FDIC/DOJ Financial Crimes Conference, Keynote Speaker (2016) (included approximately 500 government-only participants)
  • Securities Litigation and Regulatory Practice Seminar, Panelist, “Enforcement Developments” (2016)
  • ABA Business Law Section, Derivatives & Futures Law Committee Winter Meeting, Panelist, “Enforcement/Litigation Developments” (2015)
  • American Bar Association, National Institute on Securities Fraud, Panelist, “Wall Street to the Hill: The Continuing Evolution of Insider Trading Investigations” (2014); Panelist, “Enforcement Priorities” (2015)
  • National Health Care Anti-Fraud Association, Annual Training Conference, Speaker “Medicare Fraud Strike Force and Beyond” (2011, 2012); Speaker, “Summary Evidence in Health Care Prosecutions” (2012)


In Private Practice

  • Representing of a global automobile manufacturer in a criminal DOJ investigation relating to safety defects.
  • Representing a global construction company in a criminal DOJ investigation related to alleged FCPA violations.
  • Representing a Fortune 50 company in a criminal DOJ investigation relating to allegations of healthcare fraud.
  • Representing a Global 100 company in a criminal DOJ investigation relating to allegations of fraud and bribery in defense contracting.
  • Representing an international company in a criminal DOJ investigation relating to allegations of fraud in defense contracting in Africa.
  • Representation of an audit committee of a national manufacturer in an internal investigation relating to allegations of self-dealing, conflict of interest and other misconduct by executive management.
  • Representation of a Global 50 company in a criminal DOJ investigation relating to alleged FCPA violations.
  • Representation of a major financial institution in a criminal DOJ investigation relating to insider trading.
  • Co-lead trial counsel for a Fortune 100 company during a month-long arbitration of a multi-million dollar contractual dispute with former executive management.
  • Representation of a Fortune 100 company in an internal investigation relating to fraud and self-dealing.
  • Representation of a national managed-care organization in an internal review of its compliance with Medicare Advantage risk-adjustment reimbursement rules.
VIEW MORE